Literature DB >> 15776270

[Urosepsis. Current therapy and diagnosis].

M Book1, L E Lehmann, J-C Schewe, S Weber, F Stüber.   

Abstract

Urosepsis is defined as sepsis caused by urinary tract infection. This occurs in 25% of all sepsis cases. Because of the increasing incidence of sepsis, this entity will be seen more frequently in medical practice and outpatient units. The immediate identification and treatment of the septic focus is crucial. Depending on severity, early reconstitution of adequate oxygen delivery has parallel priority, therefore necessitating intensive care unit treatment within the first hours. Therapy should consist of eliminating the infectious focus, antimicrobial treatment, supportive therapy, and special sepsis therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776270     DOI: 10.1007/s00120-005-0804-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  17 in total

Review 1.  The effects of injury on the adaptive immune response.

Authors:  J A Lederer; M L Rodrick; J A Mannick
Journal:  Shock       Date:  1999-03       Impact factor: 3.454

2.  Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans.

Authors:  R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

3.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

4.  Interleukin-1 mediates hemodynamic dysfunction and release of eicosanoids and tumor necrosis factor during graded bacteremia.

Authors:  M C Santos; D S Woolley; J V Quinn; G J Slotman
Journal:  Shock       Date:  1999-06       Impact factor: 3.454

5.  Immunosuppressive effects of apoptotic cells.

Authors:  R E Voll; M Herrmann; E A Roth; C Stach; J R Kalden; I Girkontaite
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

Review 6.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 7.  Sepsis syndromes: understanding the role of innate and acquired immunity.

Authors:  A Oberholzer; C Oberholzer; L L Moldawer
Journal:  Shock       Date:  2001-08       Impact factor: 3.454

8.  The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.

Authors:  Jean-François Dhainaut; Pierre-François Laterre; Steven P LaRosa; Howard Levy; Gary E Garber; Darell Heiselman; Gary T Kinasewitz; R Bruce Light; Peter Morris; Roland Schein; Jean-Pierre Sollet; Becky M Bates; Barbara G Utterback; Dennis Maki
Journal:  Crit Care Med       Date:  2003-09       Impact factor: 7.598

9.  Interleukin-1 mediates increased plasma levels of eicosanoids and cytokines in patients with sepsis syndrome.

Authors:  G J Slotman; B Friedman; C Brathwaite; A J Mure; J V Quinn; E Shapiro
Journal:  Shock       Date:  1995-11       Impact factor: 3.454

Review 10.  The epidemiology of the systemic inflammatory response.

Authors:  C Brun-Buisson
Journal:  Intensive Care Med       Date:  2000       Impact factor: 17.440

View more
  2 in total

Review 1.  [Urosepsis and treatment].

Authors:  F M E Wagenlehner; C Lichtenstern; M A Weigand; W Weidner
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

Review 2.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.